MetaVia Inc. (NASDAQ:MTVA – Free Report) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of MetaVia in a report released on Friday, March 21st. HC Wainwright analyst E. Arce expects that the company will earn ($5.01) per share for the year. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.
MetaVia Stock Performance
NASDAQ MTVA opened at $1.58 on Monday. MetaVia has a 1-year low of $1.29 and a 1-year high of $5.30. The stock has a fifty day moving average of $1.68.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than MetaVia
- What is the Dogs of the Dow Strategy? Overview and Examples
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- What Are Dividend Challengers?
- NVIDIA Insiders Sell: This Is What It Means for the Market
- What is the NASDAQ Stock Exchange?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
